Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients With Autoimmune Tubulointerstitial Nephritis. A Preliminary Study

Shiratori-Aso, Satoka; Nakazawa, Daigo; Nishio, Saori et al.

Frontiers in medicine, 2022, 9, 827388

Permalink : https://hdl.handle.net/2115/85508

このアイテムのアクセス数:382件（2026-01-14 04:43 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.3389/fmed.2022.827388      

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
metadata only access
URI
https://hdl.handle.net/2115/85508
タイトル
Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients With Autoimmune Tubulointerstitial Nephritis. A Preliminary Study
著者
Shiratori-Aso, Satoka ; Nakazawa, Daigo ; Nishio, Saori ; Ueda, Yusho ; Eguchi, Mina ; Yokoyama, Ai ; Yoshikawa, Junpei ; Kudo, Takashi ; Watanabe-Kusunoki, Kanako ; Takeda-Otera, Sayo ; Yamamoto, Junya ; Matsuoka, Naoko ; Kaneshima, Nobuharu ; Hattanda, Fumihiko ; Iwasaki, Sari ; Tsuji, Takahiro ; Fukasawa, Yuichiro ; Atsumi, Tatsuya
著者名
Shiratori-Aso, Satoka
e-Rad_Researcher
60724135
著者名
Nakazawa, Daigo
e-Rad_Researcher
90463736
著者名
Nishio, Saori
著者名
Ueda, Yusho
著者名
Eguchi, Mina
著者名
Yokoyama, Ai
著者名
Yoshikawa, Junpei
著者名
Kudo, Takashi
著者名
Watanabe-Kusunoki, Kanako
著者名
Takeda-Otera, Sayo
著者名
Yamamoto, Junya
著者名
Matsuoka, Naoko
著者名
Kaneshima, Nobuharu
著者名
Hattanda, Fumihiko
e-Rad_Researcher
60455631
著者名
Iwasaki, Sari
e-Rad_Researcher
50462776
著者名
Tsuji, Takahiro
著者名
Fukasawa, Yuichiro
e-Rad_Researcher
20301905
著者名
Atsumi, Tatsuya
言語
英語
キーワード
tubulointerstitial nephritis
soluble interleukin-2 receptor
autoimmune disease
therapeutic response
biomarkers
発行日
2022-02-25
出版者
Frontiers Media
収録物名
Frontiers in medicine
巻(号)
9
ページ
827388
抄録
BackgroundAutoimmune tubulointerstitial nephritis (TIN) is characterized by immune-mediated tubular injury and requires immunosuppressive therapy. However, diagnosing TIN and assessing therapeutic response are challenging for clinicians due to the lack of useful biomarkers. Pathologically, CD4(+) T cells infiltrate to renal tubulointerstitium, and soluble interleukin-2 receptor (sIL-2R) has been widely known as a serological marker of activated T cell. Here, we explored the usefulness of serum sIL-2R to predict the treatment outcome in patients with autoimmune TIN. MethodsStudy Design: Single-center retrospective observational study. Participants62 patients were diagnosed of TIN from 2005 to April 2018 at Hokkaido University Hospital. Among them, 30 patients were diagnosed with autoimmune TIN and treated with corticosteroids. We analyzed the association between baseline characteristics including sIL-2R and the change of estimated glomerular filtration rate (eGFR) after initiation of corticosteroids. ResultsThe serum sIL-2R level in patients with autoimmune TIN was significantly higher than that in chronic kidney disease patients with other causes. Mean eGFR in autoimmune TIN patients treated with corticosteroids increased from 43.3 +/- 20.4 mL/min/1.73 m(2) (baseline) to 50.7 +/- 19.9 mL/min/1.73 m(2) (3 months) (Delta eGFR; 22.8 +/- 26.0%). Multivariate analysis revealed that higher sIL-2R (per 100 U/mL, beta = 1.102, P < 0.001) level was independently associated with the renal recovery. In ROC analysis, sIL-2R had the best area under the curve value (0.805) and the cutoff point was 1182 U/mL (sensitivity = 0.90, 1-specificity = 0.45). ConclusionsOur study showed that elevated serum sIL-2R levels might become a potential predictive marker for therapeutic response in autoimmune TIN.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.3389/fmed.2022.827388